Atara

Atara Bio CEO: Company’s Momentum in Cell Therapy Should Continue in 2021
Atara Bio CEO: Company’s Momentum in Cell Therapy Should Continue in 2021
BioSpace
Atara
cell therapy
Flag link:
Bayer Leaps into CAR T-Cell Therapy Scene with Atara Biotherapeutics Collaboration
Bayer Leaps into CAR T-Cell Therapy Scene with Atara Biotherapeutics Collaboration
BioSpace
Bayer
CAR-T
cell therapy
Atara
Flag link:
Upcoming events – Atara and Aslan await validating results
Upcoming events – Atara and Aslan await validating results
EP Vantage
Atara
Tab-cel
ATA188
multiple sclerosis
Aslan
varlitinib
Flag link:
Atara Reports Initial Data for Multiple Sclerosis Candidate
Atara Reports Initial Data for Multiple Sclerosis Candidate
Yahoo/Zacks.com
Atara
ATA188
clinical trials
multiple sclerosis
Flag link:
Where Will Gilead Sciences Spend Its Cash?
Where Will Gilead Sciences Spend Its Cash?
Motley Fool
Gilead Sciences
M&A
Atara
Exelixis
Flag link:
Atara brings another experienced investigator onto its off-the-shelf CAR-T quest in latest collaboration
Atara brings another experienced investigator onto its off-the-shelf CAR-T quest in latest collaboration
Endpoints
Atara
CAR-T
cancer
Flag link:
Hot Atara snags licensing deal with leading cancer center
Hot Atara snags licensing deal with leading cancer center
Bizjournals.com
Atara
cancer
Memorial Sloan Kettering
Flag link:
7 Biotech Stocks Moving Off The UBS Healthcare Conference
7 Biotech Stocks Moving Off The UBS Healthcare Conference
Yahoo/Benzinga
biotech
UBS
AcelRx
Affirmed NV
Atara
Cerulean Pharma
Endo International
Esperion Therapeutics
Immune Design
Flag link:
Amgen spin-out on deck for IPO
Amgen spin-out on deck for IPO
Seeking Alpha
Amgen
spinoffs
IPOs
Atara
Flag link:
IPO Preview: Atara Biotherapeutics
IPO Preview: Atara Biotherapeutics
Seeking Alpha
IPOs
Atara
Flag link:
Too Early To Tell For Atara Biotherapeutics IPO
Too Early To Tell For Atara Biotherapeutics IPO
Seeking Alpha
Atara
IPOs
Flag link:
Amgen spinoff Atara cranks its Series B up to $52M
Amgen spinoff Atara cranks its Series B up to $52M
Fierce Biotech
Amgen
Atara
Series B
oncology
kidney disease
Flag link: